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Increased level of exhaled nitric oxide and up-regulation
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primary lung cancer
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Summary Monocyte-macrophage series have an important role in host surveillance against cancer. The cytotoxic/cytostatic activity of
macrophages is, to a great extent, attributed to the up-regulation of inducible nitric oxide synthase (iNOS) and production of nitric oxide (NO).
Here, in 28 patients with primary lung cancer and 20 control subjects, we measured the concentration of exhaled NO and nitrite in epithelial
lining fluid (ELF) using a chemiluminescence NO analyser, and studied NOS expression in alveolar macrophages (AM) and lung tissues by
flow cytometry; immunohistochemical analysis was also undertaken. The mean fluorescence intensity (Fl) of iNOS expression in AM was
significantly increased in patients with lung cancer (tumour side 263.5 ± 15.2 Fl, normal side 232.4 ± 18.6 Fl; n = 28) compared with that in
control subjects (27.3 ± 3.2 Fl; n = 20, P< 0.001). The level of exhaled NO from cancer patients (16.9 ± 0.9 p.p.b.; n = 28) was significantly
higher than that in the control group (6.0 ± 0.5 p.p.b.; n = 20, P < 0.001). The level of nitrite was also significantly higher in ELF from cancer
patients (tumour side 271.1 ± 28.9 nm and normal side 257.4 ± 19.6 nm vs control subjects 32.9 + 4.1 nM; P< 0.001). The intensity of iNOS
expression in AM was correlated with the level of exhaled NO (rS = 0.73, n = 76, P < 0.001) and the nitrite released in ELF (r, = 0.56, n = 76,
P < 0.001). The nitrite generation of cultured AM from patients with lung cancer was significantly enhanced compared with that of control
subjects after culture for 24 h (tumour side 5.75 ± 0.69 and normal side 5.68 ± 0.58 gM per 106 cells vs control group 38.3 + 3.6 nm per 106
cells; P< 0.001). The distribution of iNOS was identified in AM, tumour-associated macrophages, endothelium, chondrocytes, airway
epithelium of both lungs and malignant cells (adenocarcinoma and alveolar cell carcinoma) of cancer patients. cNOS was labelled in alveolar
macrophages, endothelial cells and nerve elements from lung tissue. Our results indicate that, in patients with primary lung cancer, the
production of NO from alveolar macrophages was increased as a result of the up-regulation of iNOS activity. The increased NO production
was not specific to the tumour side and might be attributed to the tumour-associated non-specific immunological and inflammatory processes
of the host.
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The host defence mechanism is important in the development and
growth of tumours. The incidence of malignancy is reported to be
increased in subjects with compromised immunity (Penn, 1986).
The complex defence and immunological mechanisms against
cancer contain several types of cells, including macrophages
(Fidler et al, 1988) and mediators, such as nitric oxide (NO)
(Farias-Eisner et al, 1996).
Macrophages have a role in host surveillance against cancer
(Hibbs et al, 1978). Macrophages can be activated both in vivo and
in vitro to kill tumour cells. The oncolytic activity ofmacrophages
is either mediated by direct macrophage-to-tumour cell contact
(Bucana et al, 1983) or attributed to the production of soluble
tumour cytotoxic factors, such as tumour necrosis factor-a (TNF-
oc), interleukin I (IL-1), IL-6, cytolytic proteases, arginases, lyso-
somal enzymes, prostaglandins, oxygen radicals and reactive
nitrogen species, particularly NO (Carswell et al, 1975; Currie,
1978; Adams et al, 1980; Hibbs et al, 1988; Nathan, 1991). The
cytotoxicity of activated macrophages against tumour target cells
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is dependent on the synthesis of NO (Hibbs et al, 1988). The
production of NO from activated macrophages destroys or
prevents tumourcell division by inhibition ofDNA replication and
restraint ofmitochondrial respiration (Stuehr et al, 1989; Moncada
et al, 1991). Furthermore, the constitutive and inducible NOS is
also present in several types of tumour cells, including colorectal
adenocarcinoma (Radomski et al, 1991), gynecological carcinoma
(Thomsen et al, 1994, 1995), neuroblastoma (Forstermann et al,
1990) and dermal squamous cell carcinoma (Villiotou et al, 1995).
Thus, NO production is enhanced in patients with malignancy
either directly from tumour cells or from activated macrophages as
host defence mechanisms against tumour cells.
Recently, it has also been reported that tumour-associated NO
production increases in lung cancer, as suggested indirectly by an
increased level of nitrite/nitrate in the bronchoalveolar lavage
(BAL) fluid of lung cancer patients (squamous cell carcinoma)
(Arias-Diaz et al, 1994). However, the cellular source of NO
generation in lung cancer is still unknown. Therefore, we felt it
necessary to further characterize the role of NO in the biology of
lung cancer. In this study, we have measured NO levels in exhaled
air and explored NOS localization within lung tissues as well as
NO production capacity from alveolar macrophages. The distribu-
tion of NOS expression in lung tissue was also compared in
different types oflung cancers.
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MATERIALS AND METHODS
Patients
Twenty-eight patients with bronchogenic carcinoma proven histo-
logically before treatment, without other systemic diseases, were
enrolled in this study. To avoid the possible confounding effects of
cigarette smoking on exhaled NO levels or NOS activity, 20 of
them were non-smokers selected intentionally from our chest
clinics. Of the control subjects, five were healthy volunteers and
eight had received bronchoscopy because ofhaemoptysis. Another
five were found to have single nodular lesions on chest radio-
grams, and the remaining two presented with coughs and local
wheezing on physical examination. All of them had no abnormal
findings at bronchoscopic, microbiological and cytological inves-
tigation. Eight current smokers with lung cancer and nine of the
controls were also recruited into this study to compare the differ-
ence between smokers and non-smokers. All subjects had had no
upper respiratory tract infection within the last 6 weeks. None of
them were taking antibiotics, immunosuppressants or other regular
medication at the time of evaluation. Informed consents were
obtained from all subjects.
All patients with malignancy received complete staging,
including computerized tomography of chest, liver echography
and bone scan. The International TNM staging system was applied
for staging the patients with non-small-cell lung cancers and a
simple two-stage system for those with small-cell lung cancer,
which classified patients as having limited disease (LD) or exten-
sive disease (ED) (Abrams et al, 1988).
Histology and nomenclature of lung cancer
Tumour types were determined by histological assessment of
haematoxylin- and eosin-stained tissue sections. The carcinomas
were classified into squamous carcinoma, small-cell carcinoma,
adenocarcinoma (including alveolar cell carcinoma), undifferenti-
ated large-cell carcinoma and unclassified carcinoma according to
the WHO classification (WHO, 1981).
Measurement of exhaled nitric oxide
Exhaled NO was measured using a chemiluminescence analyser
(NOA Model 280; Sievers, Boulder, CO, USA), which was
adapted for on-line recording ofNO concentration. To decrease the
confounding effect of environment, for all subjects, exhaled NO
was sampled after inspiring NO-free gas (21% 02 and 79% N2) for
3 min. Then all subjects were asked to perform a slow vital-
capacity manoeuvre over 30-45 s into wide-bore Teflon tubing,
and NO was sampled continuously at a flow rate of
200 ml min-'. Subjects wore nose clips and were in sitting or
standing positions during the measurement of the exhaled NO
level. A high-flow mask with a one-way valve was worn when
measuring the endotracheal level of NO at the orifices of bilateral
main bronchi by bronchoscopy. Results were displayed on a chart
recorder. Three successive peak values were recorded and the
mean values analysed.
Preparation of lung cells
Bronchoalveolar lavage (BAL) was performed using three aliquots
(50 ml each) of0.9% saline solution as described previously (Kuo
et al, 1993). The total cell and differential cell counts were deter-
mined. The BAL fluid was centrifuged at 600g for 20 min at 4°C,
and the cell pellet was washed sequentially and resuspended in
RPMI-1640 (Gibco, Grand Island, NY, USA) supplemented with
5% heat-inactivated fetal calf serum (FCS, Flow Laboratories,
Paisley, UK) at 106 cells ml-'. The cell viability was determined by
trypan blue exclusion.
Culture of alveolar macrophages
Alveolar macrophages were placed in 75-cm2 plastic culture
dishes in RPMI-1640, allowed to adhere for 90 min and then
washed three times with warmed RPMI to remove non-adherent
cells. Adherent cells were scraped off with a sterile rubber
policeman and then resuspended (106 cells ml-') in RPMI-1640
containing 5% FCS, 100 U ml-1 penicillin and 100 ptg ml-' strepto-
mycin. Then the AM were placed in 12-well Petri dishes at
106 cells ml-' for 24 h at 37°C, 5% carbon dioxide. The culture
supernatant was collected and frozen at -72°C before measuring
RNI production. To determine that the generation of RNI was
specific for NO production, alveolar macrophages were cultured in
the presence or absence of a NOS inhibitor (NG-monomethyl-L-
arginine, L-NMMA, 1 mM) (Calbiochem, La Jolla, CA, USA). The
supernatant of culture medium was harvested and stored at -720C
before analysis.
Measurement of iNOS expression in alveolar
macrophages
Lavaged cells at I x 106 cells ml-' were fixed with 100 tl of 4%
paraformaldehyde at room temperature for 10 min and then washed
twice with phosphate-buffered saline (PBS) pH 7.0. The cell pellet
was resuspended in 20gl of 3.7% n-octyl-p-D-glucopyranoside
(OG, Sigma) and then incubated for 5 min at room temperature
before being washed twice with PBS. Thereafter cells were incu-
bated with anti-iNOS rabbit polyclonal (Transduction Laboratories,
Lexington, KY) diluted 1:25 in PBS (20 .tl) in the dark for 1 h at
4°C. After being washed twice with PBS, the cell pellet was
labelled with 5 ,ul of fluorescein isothiocyanate (FITC) conjugated
swine anti-rabbit IgG (Dakopatts, Glostrup, Denmark) and placed
in the dark for 30 min at 40C, and subsequently analysed by flow
cytometry after two extensive washings with cold PBS containing
5% FCS. Analysis ofthe fluorescence intensity ofiNOS in alveolar
macrophages was performed with a FACScan flow cytometer
(Becton Dickson, Mountain View, CA, USA) and Cell-Quest soft-
ware (Becton Dickson). Controls were used to give a measure of
non-specific binding using FITC-conjugated F(ab), fragments of
rabbit anti-mouse immunoglobulin (Dako, Kyoto, Japan). Results
were expressed as a mean fluorescence intensity in arbitrary units
transformed to a linear scale from the log,0 channel number of
mean fluorescence, for a particular cell marker.
Measurement of nitrite in BAL fluid and supernatant of
AM culture
To measure the concentration of nitrite, 50 tl of lavaged fluid or
culture media supernatant were added to the purge vessel
containing 5 ml of a reducing solution (1% potassium iodide in
acetic acid) that converts nitrite to nitric oxide. Quantification
of the NO formed from reactive nitrogen intermediate (RNI) was
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determined from the specific chemiluminescence resulting from
the reduction of NO with ozone using the chemiluminescence
analyser (Sievers NOA Model 280, Boulder, CO, USA).
Conversion of standard mixtures of nitrite and nitrate solutions to
NO was 94% compared with calibrated standards ofNO gas.
NOS localization by immunohistochemical study
Sections (4 ,um) were cut from formalin-fixed, paraffin-embedded
lung tissues. Two antibodies were used for NOS detection: (1) a
polyclonal rabbit antibody to iNOS from murine macrophages that
immunoreacted with human iNOS (Anti-macNOS; Transduction
Laboratories, Lexington, KY, USA) and (2) two monoclonal
mouse antibodies to cNOS from human endothelium and brain
tissue (Anti-ENOS and Anti-BNOS; Transduction Laboratories,
Lexington, KY, USA). Non-specific mouse IgG was used as a
control. After being de-waxed in xylene and rinsed in absolute
alcohol, sections were incubated in 3Yo hydrogen peroxide in
methanol for 30 min to quench endogenous peroxidase. Then the
sections were microwaved in citric acid buffer with 0.1% (v/v)
Triton X 100 for 5 min to enhance the antigen exposure and incu-
bated in 0.2% (v/v) normal swine serum (Dako, CA, USA) for
30 min to block the positive and negative charges of tissues.
Afterwards, the sections were subjected to 1-h incubation with
primary specific anti-NOS antibody (diluted 1:200) or non-
specific purified mouse IgG (diluted 1:200) as a control. Antibody
labelling was subsequently visualized using an avidin-biotin
complex method (LSAB 2 kit, Dako; DAB peroxidase substrate
kit, Vector Laboratories, Burlingame, CA, USA). The slides were
then counterstained with haematoxylin, dehydrated through
graded alcohol and xylene, mounted and coverslipped.
Statistical analysis
Standard formulas were used for the analysis. Data did not approx-
imate a Gaussian distribution, whereby the mean value did not
approximate the median value. Non-parametric statistical analyses
were therefore used, and the probability of differences between
groups was initially assessed using Kruskal-Wallis analysis. The
number of patients in some groups was too small to allow for a
strict median test between groups, and subsequent analysis was
performed using the Mann-Whitney U-test (two-tailed) to assess
the significance of differences between groups. To minimize the
possibility of obtaining chance significance as a result of multiple
comparisons, preplanned comparisons between specific groups
were made and the significant values confirmed using
Newman-Keuls analysis. Relationships between mean fluores-
cence intensity of iNOS expression in AM, the levels of exhaled
NO and nitrite in BAL fluid and supematant of AM culture
were investigated using Spearman's rank test. Data represent
means ± s.e.m. The null hypothesis was rejected at P < 0.05.
RESULTS
Patients
Twenty-eight patients with primary lung cancer (18 male and 10
female, 34-84 years of age) and 20 control subjects (13 male and
7 female, 21-63 years of age) were enrolled in this study. The
pathology and clinical characteristics of these patients are shown
in Table 1.
Table 1 Pathology and clinical characteristics of patients with primary lung
cancer
Patient characteristics Patient no.
(n = 28)
Histological cell type
Non-small-cell carcinoma 24
Squamous cell carcinoma 10
Adenocarcinoma 9
Large-cell carcinoma 5
Small-cell carcinoma 4
Clinical staging
Non-small-cell carcinoma
Stage Illb 9
Stage IV 15
Small-cell carcinoma
Limited stage 1
Extensive stage 3
Performance status
ECOG scale 1 15
ECOG scale 2 10
ECOG scale 3 3
Cellular profiles in BAL
The total cell counts retrieved in BAL fluid in the cancer patients,
either from the tumour side or from the normal side, were signifi-
cantly higher than those in the control group. The recovery rate
was significantly lower in the tumour side of cancer patients, and
viability was significantly higher in the control group. There was
no significant difference in the differential cell counts between the
two groups (Table 2).
The level of exhaled NO and expression of iNOS in
alveolar macrophages
The level of exhaled NO from the cancer patients was 16.9 ± 0.9
p.p.b. (n = 28), which was significantly higher than that from the
control subjects (6.0 ± 0.5 p.p.b., n = 20, P < 0.001) (Table 3).
There was no significant difference in NO between smokers and
non-smokers in either group (Table 3). The difference between the
cancerpatients and the control group was still significant regardless
of smoking exposure. NO measured by bronchoscopy in the cancer
patients showed no significant difference between the normal side
and the tumour side (Table 3). The magnitude of iNOS expression
in AM was significantly increased in those patients with pulmonary
malignancy, retrieved either from the tumour side or from the
normal side, compared with that in the control subjects (Table 3).
The level ofexhaled NO was correlated with the intensity of iNOS
expression in AM (r = 0.73, ni = 76, P < 0.001) (Figure 1).
Nitrite released in BAL fluid and supernatant of AM
culture
The level of nitrite was significantly higher in BAL fluid from the
cancer patients, either from the tumour side (271.1 ± 28.9 nM) or
from the normal side (257.4 ± 19.6 nM) (n = 28), than in that from
the control group (32.9 + 4.1 nm, n = 20, P < 0.001) (Table 3). The
intensity of iNOS expression in AM was significantly correlated
with the nitrite level retrieved in BAL fluid (r = 0.56, n = 76,
P < 0.001), as well as with the nitrite generation after a 24-h
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Table 2 Total cell counts and cellular populations recovered by bronchoalveolar lavage in patients with
primary lung cancer and control subjects
Patients Control subjects
(n = 28) (n = 20)
Tumour side Normal side
Total cell count (x 106) 8.28 ± 0.73a 8.72 ± 0.90a 4.12 ± 0.41
Recovered rate (% v/v) 56.0 + 1.9b 65.4 ± 2.1 67.4 ± 1.9
Cell viability (%) 88.9 ± 1.1a 91.7 + 1.0a 95.1 ± 0.47
Differential count
Alveolar macrophages (%) 85.9 ± 2.3 84.5 ± 1.9 89.0 ± 1.0
Lymphocytes (%) 10.3 + 1.8 12.2 + 2.3 9.9 ± 1.0
Neutrophils (%) 3.8+ 1.3 3.3± 1.1 1.1 +0.2
Values represent mean ± s.e.m. ap < 0.05 compared with control group. bp< 0.05 compared with normal
side of cancer patient and control group.
Table 3 NOS activity in both lungs of patients with lung cancer (n = 28), as measured by exhaled NO level, nitrite concentration in
ELF and supernatant of AM culture, fluorescence intensity of iNOS in AM and LNMMA inhibition study, compared with that in control
subjects (n = 20)
Patients Control subjects
(smokers, n = 8) (smokers, n = 9)
Tumour side Normal side
NO (p.p.b.)
Exhaled level 16.9 ±0.9a 6.0 ± 0.5
(17.5 ± 2.1a) (6.5 ± 0.6)
Endobronchial level 16.8 + 0.8a 16.2 ± 0.6a
(17.3 + 1.1a) (16.5 ± 1.2a)
iNOS in AM (Fl) 263.5 ± 15.2a 232.4 + 18.6a 27.3 ± 3.2
(261.1 + 18.8a) (250.2+ 21.4a) (29.0 ± 4.9)
Nitrite in ELF (nM) 271.1 ± 28.9a 257.4 ± 19.6a 32.9 ± 4.1
(268.7 ± 21.7a) (251.5 ± 23.2a) (37.5 ± 5.5)
Nitrite from cultured AM (nM 10-6 cells) 5750 + 690a 5677 + 579a 38.3 ± 3.6
(6403 ± 1381a) (5601 ± 1002) (43.0 ± 6.1)
Nitrite from cultured AM +LNMMA (nM 10-6 cells) 3462 ± 512a.b 3612 + 471a.b 32.4 ± 2.6
(n=23) (n=23) (n= 18)
(3596 + 742a.b) (2274 + 396ab) (32.6 ± 2.9)
Values represent mean + s.e.m. ap < 0.001 compared with control subjects. bp< 0.05 compared with corresponding group without
LNMMA treatment. AM, alveolar macrophage; ELF, epithelial lining fluid; Fl, fluorescence intensity. Data in parentheses are from
smokers in either group.
culture ofAM (rs = 0.49, n = 76, P < 0.001). The nitrite generation
by cultured AM from the patients with lung cancer was signifi-
cantly enhanced compared with that from the control subjects
(Table 3). The spontaneous production ofnitrite from cultured AM
in the cancer patients was significantly inhibited by L-NMMA, at
1 mmol ml- (n = 46, P < 0.05). In contrast, there was no signifi-
cant change in the production of nitrite from cultured AM of the
control subjects (Table 3). There was no significant difference
between smokers and non-smokers in either group (Table 3).
Immunofluorescence and immunohistochemical
staining of NOS in the lung
Inducible and constitutive forms of NOS were identified in many
constitutive elements and inflammatory cells within the lung
cancer tissues (Table 4, Figures 2 and 3). AM and tissue-associated
macrophages from patients with primary lung cancer, but not from
control subjects, were strongly labelled with anti-iNOS polyclonal
antibody (Figure 2A-E). There was weak, yet distinct staining for
iNOS on tumour cells of two adenocarcinomas and one alveolar
cell carcinoma (Figure 3A). Immunolabelling with anti-iNOS and
cNOS could not detect antigens on tumour cells of squamous
carcinomas, large-cell carcinomas, small-cell carcinomas and five
other adenocarcinomas. Sections labelled with buffer or control
IgG did not show any labelling of lung tissue (Figure 3B).
Differential expression of iNOS, nitrite production and
exhaled NO among patients with different types of lung
cancer
There was no significant difference in the exhaled NO concentra-
tion, fluorescence intensity ofiNOS activity in AM, nitrite level in
BAL fluid and supernatant of AM culture between patients with
different types oflung cancer (Table 5).
DISCUSSION
In this study, we have demonstrated that the level of exhaled NO
was greater from patients with primary lung cancer than that from
control subjects. Exhaled NO has been demonstrated to be
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Figure 1 The relationship between exhaled NO level and
iNOS expression in alveolar macrophages (expressed as m
intensity, Fl) (r= 0.73, n = 76, P < 0.001)
elevated in airway inflammatory diseases, suci
asthma and bronchiectasis (Kharitonov et al, 1995
1996), but the precise cellular source of exhaled N
In the present study, we have provided direct evider
ence and distribution ofNOS in lung tissues and f
production of nitrite from AM in patients with
cancer. The iNOS expression of AM was up-regul
with primary lung cancer compared with that
subjects. After AM culture for 24 h, the up-regulat
AM also led to an enhancement in the spontaneou
tion. The magnitude of iNOS expression in A]
related to the level ofexhaled NO and was also ass(
level ofnitrite released in BAL fluid, suggesting th;
the major cellular source ofNO production. Althou
patients with lung cancer are current or ex-smok
show that there was no significant difference i
exhaled NO, in the expression of iNOS on AM o
duction from cultured AM in current smokers,
prolonged cigarette smoking exposure might contri
extent, to the up-regulation ofNO synthesis ofAM
Here, the immunohistochemical study of the lung tissue further
indicates that AM is the major cellular source of NO production,
by revealing strong histochemical staining for anti-iNOS on AM
and tissue-associated macrophages (TAM) in patients with
primary pulmonary malignancy. There was only weak staining on
* endothelium and airway epithelium. There was no significant
difference in cNOS immunostaining in lung tissues between
patients with pulmonary malignancy and control subjects, indi-
cating that cNOS might not play a major role in the host response
to lung cancer. The increased NO production was not specific to
the tumour, with evidence of elevated levels of exhaled NO and
nitrite in BAL fluid retrieved from both sides of the lungs in the
cancer patients. In addition, only alveolar cell carcinoma and
adenocarcinoma were weakly stained for iNOS expression,
suggesting that NO production in patients with primary pulmonary
malignancy is principally derived from AM. However, further
500 600 molecular biological studies may be needed to show more conclu-
sively the presence of iNOS or cNOS within AM or tumours,
instead ofrelying on the selectivity of antibodies.
the magnitude of Although the importance of NO synthesis in rodent
iean fluorescence macrophages is well established, the existence of such a pathway
in human monocytes/macrophages is still controversial (Denis,
1994). Recent reports have shown that human monocyte-derived
macrophages generated NO when exposed to TNF-ax (Munoz-
h as bronchial Fernandez et al, 1992). It was also suggested that NOS could be
; Massaro et al, induced in human monocytes by an immunoglobulin E-dependent
TO is unknown. mechanism or by sequential treatment with IL-4 and INF-y (Kolb
nce for the pres- et al, 1994). It has been reported that matured human macrophages
or the enhanced release a substantial amount of nitrite in vitro, apparently without
i primary lung stimulation (Martin et al, 1993). In this study, we have demon-
lated in patients strated that AM retrieved from patients with lung cancer generated
in the control substantially greater amount of nitrites than those from control
tion of iNOS in subjects, and the nitrite production was attenuated by L-NMMA.
s nitrite genera- This provides evidence to indicate that human AM possess the
M was closely capacity for the production ofhigh-output NO.
ociated with the From ourresults, the functional significance ofNO production in
at AM mightbe lung cancer is not clear. Activated macrophages produce high
igh some of our levels ofNO that destroy or prevent the division oftumour cells by
:ers, our results inhibition of DNA replication and prevention of mitochondrial
in the level of respiration (Stuehr et al, 1989; Moncada et al, 1991). NO was
or in nitrite pro- demonstrated to account for the macrophage cytotoxic activities
suggesting that against tumour cells, and to be related to tumour regression (Stuehr
bute, to a trivial et al, 1989; Nathan et al, 1991; Radomski et al, 1991). However, in
1. certain mammalian cell cultures, NO was shown to be a potent
Table 4 Summary of anatomical constitutions showing immunostaining of NOS
cNOS INOS
Cancer patients Nerve Epithelium
Endothelium Gland cell
Alveolar macrophages Endothelium
Alveolar macrophage
Tumour-associated macrophage
Chondrocyte
Fibroblast
Adenocarcinoma
Alveolar cell carcinoma
Control subjects Endothelium Alveolar macrophage
Nerve elements
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Figure 2 Immunofluorescence staining with anti-iNOS polyclonal antibody conjugated with FITC of alveolar macrophages retrieved by BAL (A-D) and
immunohistochemistry study of lung tissues from patients with primary lung cancer (E). There was strong labelling of iNOS on alveolar macrophages (A) and
tumour-associated macrophages (E) from patients with primary lung cancer, but not from control subjects (C). B and D represent the modified Wright's stain of
cells as in A and C, respectively (original magnification: A-D, x 400; E, x 200)
mutagen (Mordan et al, 1993). The dual pro- and anti-tumour
action of NO was recently demonstrated to be dependent on the
local concentration of the molecules (Jenkins et al, 1995). An
inverse relationship between the generation of NO and the
metastatic potential of a tumour was also proposed (Dong et al,
1994). Thus, the extent of NO production may be related to the
stage of cancer cells and may vary with various types of cancer
cells. As the cancer patients enrolled in this study are in clinical
stage IlIb or IV, the expression of iNOS and enhanced NO genera-
tion capacity in relation to the grading of the tumour, clinical
staging and prognosis deserves further investigation. The contribu-
tion of cancer cells to generate NO seems to be trivial, as the
enhanced production of NO and the up-regulation of iNOS were
similar whetherretreived from the disease-free side ofthe patient or
from the lesion side. A complex intercellular interaction may deter-
mine whether macrophages augment or suppress anti-tumour
response (Takeo et al, 1986; Alleva et al, 1994). The actual
outcome may be related to the state of macrophage activation and
the intrinsic properties ofthe tumour cell (Walters et al, 1991).
There is evidence that NO may contribute to tumour control
during radiotherapy and may be involved in some of the thera-
peutic activities of chemotherapy by increasing nucleic acid
damage and by disruption of intracellular signalling (Sagar et al,
1995). NO also plays a fundamental role in radiation-induced
British Journal ofCancer(1998) 78(4), 534-541
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Figure 3 Immunohistochemical study of the lung tissue. A weak, yet
distinct staining for iNOS on tumour cells of one alveolar cell carcinoma
(A) was observed. Sections labelled with buffer or control IgG did not show
any labelling of lung tissue (B) (original magnification: A and B, x 200)
tissue injury and may be involved in some of the side-effects of
chemotherapy (Sagar et al, 1995). The exploration of a prognostic
role of NO (either detected in exhaled air or retrieved in BAL
fluid) in response to chemotherapy or radiotherapy may further
elucidate the biological activities ofNO in primary lung cancer.
In conclusion, our results indicate that, in human lung cancer, the
iNOS activities ofAM and TAM are up-regulated with a high output
of RNI, including NO and nitrite. Our results extend the role ofNO
in host response to pulmonary malignancy. The significance of our
results may be weighed by further studies exploring the role of NO
production in the modulation of macrophage activities against
tumours and then may be related to lung cancer staging and prog-
nosis, as well as the response to chemotherapy and radiotherapy.
Table 5 Differential expression of iNOS and nitrite production of AM and exhaled NO among patients with different types of lung cancer
Histological cell type Squamous cell carcinoma Adenocarcinoma Large-cell carcinoma Small-cell carcinoma
(n=10) (n=9) (n=5) (n=4)
Exhaled NO (p.p.b.) 17.7 ± 1.6 16.0 ± 1.0 15.8 + 2.5 18.2 ± 3.1
iNOS in AM (Fl) 229.5 + 21.3 287.9 + 26.2 245.9 ± 22.9 207.1 ± 16.3
Nitrite in ELF (nM) 256.8 + 41.8 315.8 ± 37.2 224.6 ± 30.0 216.9 ± 48.4
Nitrite from cultured 6313 ± 994 6698 ± 1046 3180 ± 1173 5406 ± 1271
AM (nM 10-6 cells)
Values represent mean ± s.e.m. There was no differential expression of iNOS and nitrite production of AM and exhaled NO among patients with different types
of lung cancer. AM, alveolar macrophage; ELF, epithelial lining fluid; Fl, fluorescence intensity.
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